Recent Progress in Non-Small Cell Lung Cancer: Prime Time for Personalized Therapy.
Hanyang Medical Reviews.2014;34(1):2-3. doi:10.7599/hmr.2014.34.1.2
Hanyang Medical Reviews
1981 to Present ISSN: 1738-429X
Sort by
DISPLAY OPTIONS
Format:
Per page:
The New Era of Evolution and Innovation in Hanyang Medical Reviews.
Hanyang Medical Reviews.2014;34(1):1-1. doi:10.7599/hmr.2014.34.1.1
No abstract available.
Developmental Strategy for Stem Cell Therapy Products in Regulatory Considerations.
Hanyang Medical Reviews.2012;32(3):163-169. doi:10.7599/hmr.2012.32.3.163
Expectation that stem cell therapy products will prove better and more effective in treating a variety of medical conditions continues to drive expanding research efforts. Stem cell therapy products consist of, or are derived from, populations of stem cell progenitors. They are complex and dynamic biological therapies which are highly regulated for safety and efficacy as biological products. The Korea Food Drug Administration (KFDA) is the legal authority responsible to regulate stem cell therapy products as stipulated by the Pharmaceutical Affairs Act. In this article, the regulatory review process used by the KFDA to assess the safety and effectiveness of novel stem-cell therapy products is described. The agency regularly updates and re-evaluates recommendations applicable to production and testing of stem cell therapy products based on the accumulation of scientific and clinical experiences.
Biological Agents ; Biological Therapy ; Informed Consent By Minors ; Korea ; Stem Cells ; Treatment Outcome
Biological Agents ; Biological Therapy ; Informed Consent By Minors ; Korea ; Stem Cells ; Treatment Outcome
Strategy for Maximizing Therapeutic Efficacy of Adult Stem Cells.
Hanyang Medical Reviews.2012;32(3):159-162. doi:10.7599/hmr.2012.32.3.159
Stem cells have been suggested for the treatment of intractable neurological diseases. In spite of numerous clinical trials using autologous mesenchymal stem cells (MSCs), unfortunately, clinical efficacy has not yet been proved except for its safety. Although there are several reasons for unsuccessful efficacy of stem cell therapy using adult stem cells, we should consider the exact factors that may improve the therapeutic efficacy of adult stem cells. One of the most important factors is the patient's age when MSCs are obtained from patients. It is associated with decreased functions of MSCs. Several reports have shown that MSCs from elderly persons have decreased capacities in the secretion of neurotrophic factors and migration to the lesion site. Therefore, procedures potentiating MSCs need to be studied during ex-vivo expansion. To suggest diverse procedures to improve capacities of MSCs for improvement of therapeutic efficacy, I will discuss previously reported methods potentiating MSCs and will suggest further experiments.
Adult ; Adult Stem Cells ; Aged ; Humans ; Mesenchymal Stromal Cells ; Nerve Growth Factors ; Neurodegenerative Diseases ; Stem Cells ; Tissue Therapy
Adult ; Adult Stem Cells ; Aged ; Humans ; Mesenchymal Stromal Cells ; Nerve Growth Factors ; Neurodegenerative Diseases ; Stem Cells ; Tissue Therapy
Clinical Applications of Neural Stem Cells for the Treatment of Peripheral Neuropathy.
Hanyang Medical Reviews.2012;32(3):154-158. doi:10.7599/hmr.2012.32.3.154
Extraordinary advances in stem cell research have initiated an era of hope for strategies to treat intractable human diseases. Personalized regenerative treatment using stem cells is expected to accelerate continuous investment and research efforts throughout the world. Despite of their constraints, adult stem cells and embryonic stem cells have been used for cell transplantation for several intractable diseases. Besides adult and embryonic stem cells, the recent studies of induced pluripotent stem cells widened the possibility of patient-specific cell therapy, drug discovery, and disease modeling. This review focuses on the developments and potential applications of the stem cells for the treatment of peripheral neuropathy.
Adult ; Adult Stem Cells ; Cell Transplantation ; Drug Discovery ; Embryonic Stem Cells ; Humans ; Induced Pluripotent Stem Cells ; Investments ; Median Neuropathy ; Neural Stem Cells ; Peripheral Nervous System Diseases ; Stem Cell Research ; Stem Cells ; Tissue Therapy ; Transplants
Adult ; Adult Stem Cells ; Cell Transplantation ; Drug Discovery ; Embryonic Stem Cells ; Humans ; Induced Pluripotent Stem Cells ; Investments ; Median Neuropathy ; Neural Stem Cells ; Peripheral Nervous System Diseases ; Stem Cell Research ; Stem Cells ; Tissue Therapy ; Transplants
Treatment Strategy for Parkinsonian Diseases Through Mesenchymal Stem Cells.
Hanyang Medical Reviews.2012;32(3):145-153. doi:10.7599/hmr.2012.32.3.145
Parkinsonian diseases including Parkinson's disease (PD) and multiple system atrophy (MSA) are neurodegenerative diseases representative of alpha-synucleinopathies characterized pathologically by alpha-synuclein-abundant Lewy bodies and glial cytoplasmic inclusions, respectively. Cell therapy using mesenchymal stem cells (MSCs) is attractive clinically because these cells are free from ethical and immunological problems. MSCs are present in adult bone marrow and represent <0.01% of all nucleated bone marrow cells. MSCs are multipotent, and differentiation under appropriate conditions into chondrocytes, skeletal myocytes, and neurons has been demonstrated thus far. According to recent studies, the neuroprotective effect of MSCs is mediated by the production of various trophic factors that contribute to functional recovery, neuronal cell survival, and endogenous regeneration of neural tissues. Additionally, MSCs appear to have immunoregulatory properties that can ameliorate the progression of disease. However, the therapeutic use of MSCs as neuroprotectives in PD and MSA has seldom been studied. Here we comprehensively review recent advances in clinical strategies using MSCs in PD and MSA, especially focusing on their neuroprotective properties in preventing or delaying disease progression and therapeutic potential for providing functional recovery.
Adult ; Bone Marrow ; Bone Marrow Cells ; Cell Survival ; Chondrocytes ; Disease Progression ; Humans ; Inclusion Bodies ; Lewy Bodies ; Mesenchymal Stromal Cells ; Multiple System Atrophy ; Muscle Fibers, Skeletal ; Neurodegenerative Diseases ; Neurons ; Neuroprotective Agents ; Parkinson Disease ; Parkinsonian Disorders ; Regeneration ; Tissue Therapy
Adult ; Bone Marrow ; Bone Marrow Cells ; Cell Survival ; Chondrocytes ; Disease Progression ; Humans ; Inclusion Bodies ; Lewy Bodies ; Mesenchymal Stromal Cells ; Multiple System Atrophy ; Muscle Fibers, Skeletal ; Neurodegenerative Diseases ; Neurons ; Neuroprotective Agents ; Parkinson Disease ; Parkinsonian Disorders ; Regeneration ; Tissue Therapy
Recent Trends and Strategies in Stem Cell Therapy for Alzheimer's Disease.
Hanyang Medical Reviews.2012;32(3):141-144. doi:10.7599/hmr.2012.32.3.141
The human mesenchymal stem cell (MSC) has been regarded as a fascinating candidate of stem cell therapy in neurodegenerative disorders such as Alzheimer disease (AD). Recently, many groups reported that mesenchymal stem cell is a robust source, not only of regeneration, but also of secretion of various soluble factors for damaged or lost host cells. Several groups have observed paracrine action of mesenchymal stem cells in transgenic mice models of AD. From non-clinical studies we can conclude that human mesenchymal stem cells could participate in anti-apoptosis, beta-amyloid removal, anti-inflammation and anti-tau aggregation via paracrine action. Based on these findings, several clinical trials have been performed or completed worldwide. Since safety and efficacy have been confirmed from various non-clinical and clinical trials, we can expect emerging use of stem cells for AD in the near future.
Alzheimer Disease ; Animals ; Humans ; Mesenchymal Stromal Cells ; Mice ; Mice, Transgenic ; Neurodegenerative Diseases ; Regeneration ; Stem Cells
Alzheimer Disease ; Animals ; Humans ; Mesenchymal Stromal Cells ; Mice ; Mice, Transgenic ; Neurodegenerative Diseases ; Regeneration ; Stem Cells
Current Status and Therapeutic Perspectives for the Stem Cells Treatment of Ischemic Stroke.
Hanyang Medical Reviews.2012;32(3):134-140. doi:10.7599/hmr.2012.32.3.134
Recent attention has focused on the use of stem cells for therapy following ischemic stroke. Our understanding of brain injury following ischemic stroke has benefitted from a number of studies elucidating the causes and pathways leading to neuronal injury and death after anoxic insult. Other paths of research have provided the technology to create and manipulate stem cells along specific neuronal pathways. Therefore, researchers and clinicians have begun basic studies in the use of stem cell therapies to limit injury to the central nervous system and repair and regenerate injured neural tissues following hypoxia due to stroke. These therapies are showing promise and potential in improving the outcome of the stroke patient. This review covers our current knowledge and views concerning mechanisms of tissue damage following ischemic stroke, and the mechanisms by which stem cell therapy is predicted to benefit patients facing potential brain damage and loss of function. Recent reports of clinical trials using stem cells for stroke therapy are evaluated and critical points requiring further work and research are discussed.
Anoxia ; Brain ; Brain Injuries ; Brain Ischemia ; Central Nervous System ; Humans ; Neurons ; Stem Cells ; Stroke
Anoxia ; Brain ; Brain Injuries ; Brain Ischemia ; Central Nervous System ; Humans ; Neurons ; Stem Cells ; Stroke
Current Status and Future Perspectives of Stem Cells and Regenerative Medicine.
Hanyang Medical Reviews.2012;32(3):127-133. doi:10.7599/hmr.2012.32.3.127
Stem cells and regenerative medicine are emerging and promising fields both in academic and industry points of views. They are currently under active investigation worldwide and their market size is expected to grow rapidly in the near future. The Korean government is also investing a huge amount of money on these fields to promote R&D and product commercialization. However, its technical maturity is still in its infant state and many hurdles should be resolved to accelerate technology to business. I can definitely say that we have to focus in the future on innovations in technology, regulations and reimbursement. In particular, the importance of translational research and clinical studies are of no doubt in the stem cells and regenerative medicine. I am going to deal with some of these issues in more detail in the main text.
Commerce ; Humans ; Infant ; Regenerative Medicine ; Social Control, Formal ; Stem Cells ; Translational Medical Research
Commerce ; Humans ; Infant ; Regenerative Medicine ; Social Control, Formal ; Stem Cells ; Translational Medical Research
Statistics and Medical Cost of Preterm in Korea.
Hanyang Medical Reviews.2009;29(4):386-390. doi:10.7599/hmr.2009.29.4.386
This article reviews the neonatal birth rate, premature birth rate, premature survival rate and the neonatal treatment costs in Korea. The neonatal birth rate has decreased steadily during past 40 years, which is a serious social problem. However, the premature birth rate has increased by about 8~9 % because most complicated pregnancies were early delivered and the social environment has changed. The survival rate of the preterm has increased remarkably due to improvements in neonatology in Korea from 40% in 1980, to 71% in 1990, and to 78% in 2000. The newest report in 2007 for survival rates of the preterm was 95.3% for low birth weight infants, 84.7% for very low birth weight infants and 67.7% for extremely low birth weight infants. The average total hospitalization cost per person who were admitted in the neonatal intensive care unit was 4,360,000 won. The portion of the hospitalization cost covered by the National health insurance was 77.1% and 22.9% of the total hospitalization cost was not covered by the National health insurance. The hospitalization cost increased as the birth weight decreased and as the hospitalization period increased.
Birth Rate ; Birth Weight ; Health Care Costs ; Hospitalization ; Humans ; Infant ; Infant, Low Birth Weight ; Infant, Newborn ; Infant, Very Low Birth Weight ; Intensive Care, Neonatal ; Korea ; National Health Programs ; Neonatology ; Pregnancy ; Premature Birth ; Social Environment ; Social Problems ; Survival Rate
Birth Rate ; Birth Weight ; Health Care Costs ; Hospitalization ; Humans ; Infant ; Infant, Low Birth Weight ; Infant, Newborn ; Infant, Very Low Birth Weight ; Intensive Care, Neonatal ; Korea ; National Health Programs ; Neonatology ; Pregnancy ; Premature Birth ; Social Environment ; Social Problems ; Survival Rate
Country
Republic of Korea
Publisher
Hanyang University College of Medicine
ElectronicLinks
http://synapse.koreamed.org/LinkX.php?code=0130HMREditor-in-chief
Seung Hwan Lee
shleemd@hanyang.ac.kr
Abbreviation
Hanyang Med Rev
Vernacular Journal Title
한양의대학술지
ISSN
1738-429X
EISSN
2234-4446
Year Approved
2007
Current Indexing Status
Suspended(2024)
Start Year
1981
Description
Hanyang Medical Reviews (Hanyang Med Rev) is a peer-reviewed open access journal of medicine, published by Hanyang University College of Medicine. Initially launched as Hanyang Journal of Medicine (ISSN 0254-5042) in 1981 covering original articles, review articles and case reports, it was reborn as Hanyang Med Rev (ISSN 1738-429X) in 2005. Hanyang Med Rev aims at publishing review articles from different disciplines of medical sciences. Hanyang Med Rev is published quarterly and issuing dates are the 25th of February, May, August, and November. Only invited review articles on carefully selected subjects are permitted after being reviewed by the leading experts in the respective fields. Hanyang Med Rev welcomes suggestions on the topics to be discussed across the whole range of biomedical research.
Powered by IMICAMS(
备案号: 11010502037788, 京ICP备10218182号-8)